Kosan Biosciences, Inc:Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-17

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Kosan Biosciences is a cancer therapeutics company engaged in advancing two new classes of anti-cancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. The company's proprietary technologies, utilized for developing polyketides, have resulted in a potential product pipeline for the company in the oncology field.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    Kosan Biosciences currently has no marketed products. The company's product portfolio includes five potential candidates in development. These include: Tanespimycin, for the treatment of relapsed-refractory multiple myeloma, metastatic melanoma and HER2-positive metastatic breast cancer.

    Alvespimycin, being developed in intravenous and oral dosage forms for the treatment of HER2-positive metastatic breast cancer and solid tumors; KOS-1584, for the treatment of advanced solid tumors; and KOS-2187, for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).

    The company's total revenues increased at a CAGR of 8.9% during 2002-2006, from $9.6 million to $13.5 million. This represents an absolute total growth of +$3.9 million for total revenues. The company's only contributor to revenue growth during 2002-2006 was revenues from license, collaboration and others.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: tanespimycin kosan como la competitors chaitan es manufacture 22 kos1022

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.